Option chain shows key data for AXIM Biotechnologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AXIM Biotechnologies.

AXIM Biotechnologies (OTC:AXIM) Stock, Option Chain

AXIM Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.

Screenshot 2024-04-01 at 10.10.47 PM

Biotech

General

AXIM

Can The Eyes Indicate A Disease Like Parkinson&#39;s?

Penny Stocks

Emerging Markets

Health Care

Markets

SMMNY

During the last few years of the COVID-19 pandemic, the term “rapid test” conjures images of overlong cotton swabs reaching heretofore untouched corners of nasal cavities. 

In reality, rapid tests aid doctors and medical professionals of all stripes in making proper and on-the-spot diagnoses of myriad conditions.

Will This Dry Eye Rapid Test Prove To Be A Rapid Success?

Cannabis

News

MJNA

NPTX

Medical Marijuana, Inc. (OTCPK:MJNA) released its financial results for the quarter ending March 31, 2022, revealing $7.8 million in net revenue, a 24% increase when compared to the previous quarter.

Q1 2022 Financial and Operational Highlights

Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022

AXIM BIOTECHNOLOGIES INC by Axim Biotechnologies, Inc.

Comments

AXIM Biotechnologies

AXIM Biotechnologies (AXIM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga